A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer - Concepedia

Concepedia

Publication | Closed Access

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

137

Citations

8

References

2015

Year

Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Charles Erlichman, Kyriakos P. Papadopoulos, Janet L. Lensing, Muralidhar Beeram, Julian R. Molina, Drew Rasco, Rebecca R. Arcos,

Clinical Cancer Research

Abstract

Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer.

References

	Year	Citations

Page 1